ArticleNature2024
Discovery of a structural class of antibiotics with explainable deep learning.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 1 pooled it
73.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
210 citing papers in PubMed, 1 synthesis or guideline pooled it, 370 citations in OpenAlex.
- Mapping knowledge landscapes and emerging trends in artificial intelligence for antimicrobial resistance: bibliometric and visualization analysis.Frontiers in medicine · 2025Pooled it
- Artificial intelligence catalyzes antimicrobial peptide design.Synthetic and systems biotechnology · 2027Review
- Decoding cancer with artificial intelligence: Transforming research, diagnosis, and therapy with future insights.Translational oncology · 2026Review
- Target discovery and drug design in the era of artificial intelligence.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- PPAOT predictor: ARKA-RASTR strategy-driven rodent acute oral toxicity prediction for pyrazole and pyrrolidine scaffolds-based chemicals with intelligent mechanistic interpretation.Archives of toxicology · 2026Article
- Machine Learning-Guided Discovery of Bacterial-Selective Membrane-Active Compounds Reveals Mechanistic Bias in Antibiotic Training Datasets.bioRxiv : the preprint server for biology · 2026Article
- Artificial Intelligence-Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Global Research Trends and Insights on AI Usage in Tuberculosis: Bibliometric Analysis.JMIR medical informatics · 2026Article
- A Quantitative Electrostatic Potential Descriptor Enables Deep Learning-Accelerated Discovery of High-Performance Lithium-Ion Battery Electrolytes.Angewandte Chemie (International ed. in English) · 2026Article
- Identification of chemical features for improved outer membrane permeation in mycobacteria using machine learning.Nature microbiology · 2026Article
- Frontier AI companies as biotech acquirers.Nature biotechnology · 2026Article
- Bridging the AI Divide in Drug Discovery: Practical Lessons from Capacity Strengthening in Africa.Journal of medicinal chemistry · 2026Article
- TPPS4 inhibits PEDV by stabilizing viral RNA G-quadruplex and promoting ER stress: a transfer-learning-driven discovery.Journal of virology · 2026Article
- Artificial intelligence research in journals indexed in the web of science "infectious diseases" category: a bibliometric analysis, 2016-2025.Infection · 2026Article
- Reimagining antimicrobial resistance: AI-driven predictive epidemiology and the C-AMRE framework for next-generation antibiotic discovery.The Journal of antibiotics · 2026Review
- Advances in the application of artificial intelligence-driven multi-modal imaging technologies in the comprehensive diagnosis and treatment of diabetic foot ulcers.Reviews in endocrine & metabolic disorders · 2026Review
- Addressing antimicrobial resistance: Current challenges, emerging strategies, and an AI-powered, community-driven approach.PNAS nexus · 2026Review
- The Pharmacology of Bacterial Persistence: From Antibiotic Tolerance to Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Active Learning for Generalizable Detonation Performance Prediction of Energetic Materials.Chemistry of materials : a publication of the American Chemical Society · 2026Article
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
150 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 2 institutions in 3 countries.
Felix Wong *Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-2309-8835
Erica J Zheng *Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jacqueline A ValeriInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-3430-5924
Nina M DonghiaWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
Melis N AnahtarInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Satotaka OmoriInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Alicia LiIntegrated Biosciences, San Carlos, CA, USA.
Andres Cubillos-RuizInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Aarti KrishnanInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7936-4442
Wengong JinEric and Wendy Schmidt Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0555-3056
Abigail L MansonInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-3800-0714
Jens FriedrichsLeibniz Institute of Polymer Research and the Max Bergmann Center of Biomaterials, Dresden, Germany.ORCID 0000-0002-7166-6120
Ralf HelbigLeibniz Institute of Polymer Research and the Max Bergmann Center of Biomaterials, Dresden, Germany.ORCID 0000-0002-8326-9499
Behnoush HajianCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Dawid K FiejtekCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Florence F WagnerCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Holly H SoutterCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Ashlee M EarlInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0001-7857-9145
Jonathan M StokesInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Lars D RennerLeibniz Institute of Polymer Research and the Max Bergmann Center of Biomaterials, Dresden, Germany.ORCID 0000-0003-0178-1788
James J CollinsInfectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. jimjc@mit.edu.ORCID 0000-0002-5560-8246
Broad Institute · USLeibniz Institute of Polymer Research · DE
Funding
Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI SABETI, PARDIS CHRISTINE · 2014 to 2024
$66.5MMOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6MGenetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosisR01AI146194 · NIAID · UNIVERSITY OF WASHINGTON · PI ALLAND, DAVID, SHERMAN, DAVID R · 2020 to 2024
$4.1MPhysical Biology and Deep Learning for Antibiotic Resistance and DiscoveryK25AI168451 · NIAID · BROAD INSTITUTE, INC. · PI Felix Wong · 2023 to 2026
$486kNCI NIH HHS T32 CA009216NIAID NIH HHS K25 AI168451NIAID NIH HHS R01 AI146194NIAID NIH HHS U19 AI110818
Abstract
The discovery of novel structural classes of antibiotics is urgently needed to address the ongoing antibiotic resistance crisis
Indexed as
Anti-Bacterial AgentsDeep LearningDrug DiscoveryAlgorithmsAnimalsDisease Models, AnimalHumansMethicillin-Resistant Staphylococcus aureusMiceMicrobial Sensitivity TestsNeural Networks, ComputerSkinStaphylococcal InfectionsStaphylococcus aureusVancomycin-Resistant EnterococciAnti-Bacterial Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.